Cancer Investigation最新文献

{"title":"The Effect of Hand Massage on Quality of Life After Mastectomy: A Randomized Controlled Trial.","authors":"Zahra Rostami, Mansooreh Azizzadeh Forouzi, Parvin Mangolian Shahrbabaki, Mohamed Alnaiem, Tori Canillas-Dufau, Mahlagha Dehghan","doi":"10.1080/07357907.2025.2599384","DOIUrl":"10.1080/07357907.2025.2599384","url":null,"abstract":"<p><p>This randomized controlled trial aimed to evaluate the effect of Swedish hand massage on the quality of life of women undergoing mastectomy. The study was conducted on 42 women who referred to oncology centers in Kerman from February 18 to June 22, 2023. Participants were randomly assigned to intervention and sham groups through block randomization. Data were collected using a demographic and background information questionnaire and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). The intervention group received Swedish massage twice a week for three weeks, with each session lasting 20 min, while the sham group received only light surface touch for the same duration. The quality of life was evaluated at three time points: before the intervention, immediately after the end of the intervention, and one month later. Data were analyzed using SPSS version 25, with a significance level set at <i>p</i> < 0.05. The findings showed that the mean functioning score significantly increased in the intervention group compared with the sham group immediately after the massage (72.66 ± 7.14 vs. 59.98 ± 12.97; <i>p</i> = 0.007), and the mean symptom score significantly decreased (11.79 ± 6.84 vs. 22.62 ± 5.02; <i>p</i> = 0.002). Moreover, the global health status improved significantly in the intervention group immediately after the intervention (74.57 ± 8.92 vs. 52.36 ± 10.91; <i>p</i> < 0.001). Therefore, Swedish hand massage can be considered a safe, effective, and low-cost non-pharmacological method to improve the quality of life in women after mastectomy surgery.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"316-327"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145833161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact and Evaluation of Immune Checkpoint Inhibitors on Clinical Survival in Patients with Advanced Osteosarcoma: A Systematic Review and Meta-Analysis.","authors":"Yanbing Li, Zijun Li, Lingyu Cai","doi":"10.1080/07357907.2025.2599376","DOIUrl":"10.1080/07357907.2025.2599376","url":null,"abstract":"<p><p>Osteosarcoma is an aggressive bone cancer primarily affecting children and adolescents, with low survival rates in advanced stages. A systematic review and meta-analysis were conducted following PRISMA guidelines to evaluate the impact of ICIs on survival and toxicity in advanced osteosarcoma. ICIs show potential in treating advanced osteosarcoma but are associated with significant toxicity and uncertain survival benefits. Further research is needed to define their role and identify biomarkers for predicting response. Close monitoring for adverse events is essential.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"350-362"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145833283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunomodulatory Effect of First-Line Cisplatin Versus Carboplatin in Response to Second-Line Nivolumab Therapy in Metastatic Non-Small Cell Lung Cancer.","authors":"Orhun Akdogan, Hatice Bolek, Kadriye Baskurt, Busra Akay Hacan, Osman Sutcuoglu, Kadriye Bir Yucel, Berna Oksuzoglu, Cengiz Karacin, Hakan Akbulut, Fatih Gürler, Nuriye Yildirim Ozdemir, Ahmet Ozet, Ozan Yazıcı","doi":"10.1080/07357907.2025.2598042","DOIUrl":"10.1080/07357907.2025.2598042","url":null,"abstract":"<p><strong>Background: </strong>Non-small cell lung cancer (NSCLC) treatment often involves a combination of first-line immunotherapy (IO) and chemotherapy, with platinum-based regimens as alternatives. Nivolumab monotherapy is a widely used second-line treatment post-platinum chemotherapy. This is the first study to explore the immunomodulatory effects of cisplatin in advanced NSCLC patients receiving nivolumab.</p><p><strong>Methods: </strong>This retrospective study included 186 metastatic NSCLC patients from four centers in Turkey. All patients received nivolumab after progression on platinum-based chemotherapy. Multivariate Cox regression was performed to identify independent prognostic factors for progression-free survival (PFS) and overall survival (OS).</p><p><strong>Results: </strong>Patients treated with cisplatin-based chemotherapy (<i>n</i> = 91) had significantly longer median PFS (7.2 months vs. 4.9 months, <i>p</i> = 0.034) and OS (16.0 months vs. 9.9 months, <i>p</i> = 0.014) compared to those treated with carboplatin (<i>n</i> = 95). Cisplatin-based chemotherapy and ECOG performance status were identified as independent prognostic factors for both PFS and OS.</p><p><strong>Conclusion: </strong>This study highlights the potential immunomodulatory effects of cisplatin, demonstrating improved survival outcomes in NSCLC patients treated with nivolumab. Specifically, our results reveal cisplatin's unique capacity to modulate the tumor microenvironment, offering a novel avenue for optimizing checkpoint inhibitor therapy. These findings underscore the importance of platinum selection in enhancing immunotherapy efficacy and provide a basis for prospective studies to refine clinical guidelines.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"248-256"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145833178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and Validation of a Prognostic Risk-Scoring Model Based on LATS2 Expression in Acute Myeloid Leukemia.","authors":"Bin Liu, Jian Zhang, Jing Wang, Qian Wang, Xiaoman Liu, Hui Sun","doi":"10.1080/07357907.2025.2599383","DOIUrl":"10.1080/07357907.2025.2599383","url":null,"abstract":"<p><p>Acute myeloid leukemia (AML)'s treatment and remission remains unsatisfactory. A prognostic risk-scoring model containing seven signature genes (POU3F1, RPGR, PTP4A3, SOCS1, FAM83G, GREB1 and COL2A1), was developed by LASSO-Cox regression analysis. In the training set, the test group, area under the curve values of 1, 3, and 5 years were 0.876, 0.877, 0.937, and 0.974, 0.878, 0.976 respectively, which indicates a good predictive efficacy. In the two external GEO (GSE71014 and GSE6891) datasets, area under the curve values of 1, 3, 5 years were 0.847, 0.857, 0.822, and 0.830, 0.863, 0.891 respectively. Our seven signature genes containing risk-scoring model performed excellently in evaluating the OS of AML patients.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"305-315"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145833144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-Marketing Safety of Tazemetostat in Antitumor Therapy: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.","authors":"Chunyong Xia, Jie Liu, Lanxin Hu, Jun Chen, Lei Zhang","doi":"10.1080/07357907.2025.2598038","DOIUrl":"10.1080/07357907.2025.2598038","url":null,"abstract":"<p><strong>Background: </strong>Tazemetostat is an oral inhibitor of enhancer of zeste homolog 2 (EZH2) and is used for the treatment of epithelioid sarcoma (ES) and follicular lymphoma (FL). In this study, we investigated the adverse events (AEs) of tazemetostat based on real data from the U.S Food and Drug Administration(FDA) Adverse Event Reporting System (FAERS).</p><p><strong>Methods: </strong>To quantify the signals of AEs associated with tazemetostat, we employed disproportionality analyze, including the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) algorithms.</p><p><strong>Results: </strong>A total of 7,133,678 reports of AEs were collected from the FAERS database, of which 1,110 reports were identified with tazemetostat as the \"primary suspect (PS)\". A total of 32 significant disproportionality preferred terms(PTs) conforming to the four algorithms were simultaneously retained. There were multiple unexpected AEs caused by tazemetostat that were not mentioned in the label yet, including pleural effusion (ROR = 3.84, PRR = 3.83, IC = 3.83, IBGM = 1.94), lymphadenopathy (ROR = 3.88, PRR = 3.88, IC = 3.87, IBGM = 1.95) and taste disorder(ROR = 20.48, PRR = 20.23, IC = 20.16, IBGM = 4.33). Additionally, the majority of tazemetostat-associated AEs occurred within the first month of treatment initiation (<i>n</i> = 126, 49.8%).</p><p><strong>Conclusion: </strong>Clinicians need to monitor safety for tazemetostat during the first 30 days and pay more attention to new AE signals.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"239-247"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145793303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination Hormonal Drug Therapy Inhibits <i>In Vitro</i> Growth of Adult Ovarian Granulosa Tumor Cells.","authors":"Rebekah M Summey, Marissa Iden, Shirng-Wern Tsaih, Rachel Schmidt, Deepak Parashar, Shunping Wang, Janet S Rader, Elizabeth Hopp","doi":"10.1080/07357907.2025.2599380","DOIUrl":"10.1080/07357907.2025.2599380","url":null,"abstract":"<p><p>This study investigated the mechanism of action and <i>in vitro</i> efficacy of an anti-hormonal combination drug regimen in treating adult-type granulosa cell tumors of the ovary (AGCT). Using patient-derived and commercial AGCT cell lines, the IC₅₀ values of bicalutamide, anastrozole, and leuprolide acetate were established alone and in combination via cell proliferation assays. Averaged across cell lines, IC₅₀ was determined for bicalutamide (IC₅₀: 7.3 µM) and anastrozole (IC₅₀: 6.2 µM). Minimal effect was seen with leuprolide acetate alone. Suppression of proliferation was increased with the combination of an antiandrogen and an aromatase inhibitor. RNA was extracted from treated and untreated cells. RNA sequencing of cells treated with both anastrozole and darolutamide suggested downregulation of pathways involved in DNA synthesis, cell cycle regulation, and chromosomal organization. MHC I activity and DNA damage response were upregulated. This anti-hormonal drug regimen for AGCT merits prospective investigation.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"279-295"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145833126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significance and Implications of Prostate Cancer: Critical Overview for Future Directions in Africa.","authors":"Blessing Kwabena Gayi, Albert Fynn Aiduenu, Aboagye Kwarteng Dofuor, Stephen Tawiah-Nyarko, Seyram Kofi Loh, Jennifer Afua Afrifa Yamoah, William Ekloh, Angelina Akomea, Susanna Awinsongya Anovunga, Andy Asafu-Adjaye","doi":"10.1080/07357907.2025.2598046","DOIUrl":"10.1080/07357907.2025.2598046","url":null,"abstract":"<p><p>Prostate cancer places a heavy economic burden on health care in many countries globally. This is no exception in Africa. It is also described as one of the main factors in mortality rates among men of African descent. The fact that less than 40% of its patients usually present with localized disease may suggest that the projected data from above might have underestimated the disease condition in the sub-Saharan region. From the results of prostate cancer screening, an estimate can be made that most African men in the subregion do not have good information about the disease. Even though current treatment modalities for the disease are effective when used in combination, it largely remains incurable. In this review, we critically explore the impacts of prostate cancer for the benefit and future directions of the African continent. We highlight important detection and treatment strategies and summarize the economic impacts and epidemiological patterns with associated risk factors within the African population. We also discuss the potential of African medicinal plants in the fight against the disease. Furthermore, the application of artificial intelligence in enhancing detection and treatment outcomes is highlighted. This overview provides valuable insights for healthcare practitioners, policymakers, and researchers in African prostate cancer management and prevention efforts.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"328-349"},"PeriodicalIF":2.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145932366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Costs of Metastatic and Unknown Primary Cancers in Alberta, Canada, 2017-2021.","authors":"A Waye, N Thanh, A Scott, T Bond, D Stewart","doi":"10.1080/07357907.2025.2599381","DOIUrl":"10.1080/07357907.2025.2599381","url":null,"abstract":"<p><p>Given the aggressive symptomatic nature of Cancer of Unknown Primary (CUP) and non-standardized diagnostic approaches, it is expected that the cost of CUP diagnosis is higher than other cancers. This study aims to investigate the diagnostic costs of CUP as compared to other types of metastatic cancer and non-metastatic cancers over a 5-year period in the provincial health authority of Alberta, Canada. Health service utilization (inpatient, outpatient, physician services) and associated costs were compared in the 6-months prior to the diagnostic date, to the baseline period for CUP and non-CUP patients. Costs were estimated using claims amounts paid to physicians and by multiplying the resource intensity weight with the cost per standard hospital stay in Alberta. Diagnostics for CUP cost $9005 per-patient, which were 1.8x more costly than other metastatic cancers ($5027). These higher costs were driven by a large proportion of patients being diagnosed in hospital. Our findings revealed that the per-patient cost of a CUP hospital diagnosis ($13,925) was 10x that of a CUP community diagnosis ($1225) and community diagnosis of a stage IV cancer ($1426). Potential benefits exist in streamlining efforts to diagnose early, improve patient health outcomes, and reduce overall system costs of diagnosing CUP.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"296-304"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145833103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Cancer Detection in Mammography Images Using Transfer Learning Model.","authors":"Ranjini K, Mouleeswaran S K","doi":"10.1080/07357907.2025.2599378","DOIUrl":"10.1080/07357907.2025.2599378","url":null,"abstract":"<p><p>Breast cancer remains a significant global health concern, emphasizing the need for advanced and accurate diagnostic tools. This research paper focuses on the application of a Transfer Learning model for the detection of breast cancer in mammography images. Leveraging the power of deep learning, Transfer Learning enables the utilization of pre-trained models on large datasets, optimizing performance even with limited data availability. The study employs a diverse dataset comprising mammography images from various sources, ensuring a comprehensive representation of breast cancer cases. A Convolutional Neural Network (CNN) architecture, pre-trained on a vast dataset, is fine-tuned using the mammography dataset to harness its feature extraction capabilities for breast cancer detection. This approach allows the model to learn intricate patterns and abnormalities indicative of malignancies. Key steps involve the pre-processing of mammography images to enhance the quality and extraction of relevant features through the Transfer Learning model. The research investigates the model's efficacy in distinguishing between benign and malignant cases, evaluating its accuracy, sensitivity, specificity, and precision. The research proposed EfficientNet B3 with a DenseNet transfer learning model for classifying mammography images into benign or malignant categories. Also, the impact of varying architectures and hyperparameters on the model's performance is explored for optimization. Results demonstrate promising outcomes, with the Transfer Learning model exhibiting a high degree of accuracy in breast cancer detection. The model's ability to generalize across diverse datasets underscores its robustness and potential for real-world clinical applications. Visions gained from this research contribute to the ongoing discourse on the integration of advanced technologies in breast cancer diagnostics. This research signifies a crucial step towards enhancing the accuracy and efficiency of breast cancer detection, emphasizing the potential of Transfer Learning in revolutionizing mammography-based diagnostic approaches. Findings show that the EfficientNet-B3 and DenseNet have loss values ranging between 0.9, while VGG16's loss values are significantly higher, ranging from 7. The findings hold implications for improving early detection, facilitating timely interventions, and ultimately advancing outcomes for individuals at risk of breast cancer.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"257-278"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145793397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of Acute Kidney Injury in Patients Prescribed Immune Checkpoint Inhibitor Therapy and Their Association with Death: A Systematic Review and Meta-Analysis.","authors":"Jingying Sun, Xiyou Zhang, Yang Luo","doi":"10.1080/07357907.2025.2595304","DOIUrl":"10.1080/07357907.2025.2595304","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) are a novel and promising anti-cancer therapy. We conducted this systematic review to precisely quantify the occurrence and development for actue kidney injury(AKI) following ICIs treatment for cancer. We conducted a search of the PubMed, Embase, Web of Science, and Cochrane Library databases. Twenty-nine studies, comprising 24,953 cancer patients who received ICIs were finally eligible. The incidence of AKI was 16.2% (95%CI:12.8%-19.8%); the incidence of immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) was 3.1%(95%CI:2.4%-4%); the incidence of non-ICPi-AKI was 11.2%(95%CI:8.4%-14.3%), and the incidence of sustained AKI was 14.9%(95%CI:7.5%-24.3%). Patients who developed AKI (HR = 1.521(95%CI:1.208-1.916)) and ICPi-AKI (HR = 1.407(95%CI:1.059-1.869)) exhibited an elevated risk of all-cause mortality. An increased risk for AKI was observed with preexisting chronic kidney disease (CKD) and combined with other extrarenal immune-related adverse events (irAEs). The use of nonsteroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitor (PPI), diuretic, renin-angiotensin-aldosterone system (RAASi), antibiotics and fluidone was also significantly associated with incident AKI. Combined therapy had a greater impact on renal injury compared to monotherapy. Patients using ipilimumab were more prone to developing AKI, compared to those using nivoluma. CTLA4 (ref'PD-1) was associated with a higher likelihood of sustained AKI. The use of PDL-1(ref='PD-1) was linked to an increased susceptibility to ICPi-AKI. The occurrence of AKI was intricately linked to specific complications, the concomitant use of certain medications, and the specific regimen of ICIs. This deserves our attention.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"109-126"},"PeriodicalIF":1.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145667039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}